IL135920A0 - 2-aryl -8-oxodihydropurine derivative, process for the preparation thereof, pharmaceutical composition containing the same and intermediate therefor - Google Patents

2-aryl -8-oxodihydropurine derivative, process for the preparation thereof, pharmaceutical composition containing the same and intermediate therefor

Info

Publication number
IL135920A0
IL135920A0 IL13592098A IL13592098A IL135920A0 IL 135920 A0 IL135920 A0 IL 135920A0 IL 13592098 A IL13592098 A IL 13592098A IL 13592098 A IL13592098 A IL 13592098A IL 135920 A0 IL135920 A0 IL 135920A0
Authority
IL
Israel
Prior art keywords
aryl
preparation
pharmaceutical composition
composition containing
same
Prior art date
Application number
IL13592098A
Other languages
English (en)
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of IL135920A0 publication Critical patent/IL135920A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13592098A 1997-12-03 1998-11-26 2-aryl -8-oxodihydropurine derivative, process for the preparation thereof, pharmaceutical composition containing the same and intermediate therefor IL135920A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP35000097 1997-12-03
PCT/JP1998/005320 WO1999028320A1 (fr) 1997-12-03 1998-11-26 Derives de 2-aryl-8-oxodihydropurine, procede de production de ces derives, compositions medicales contenant ces derives, et intermediaires de ces derives

Publications (1)

Publication Number Publication Date
IL135920A0 true IL135920A0 (en) 2001-05-20

Family

ID=18407561

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13592098A IL135920A0 (en) 1997-12-03 1998-11-26 2-aryl -8-oxodihydropurine derivative, process for the preparation thereof, pharmaceutical composition containing the same and intermediate therefor

Country Status (27)

Country Link
US (1) US6372740B1 (pt)
EP (1) EP1036794B1 (pt)
JP (1) JP3815966B2 (pt)
KR (1) KR100494347B1 (pt)
CN (1) CN1146566C (pt)
AR (1) AR017796A1 (pt)
AT (1) ATE248169T1 (pt)
AU (1) AU744014B2 (pt)
BR (1) BR9815140A (pt)
CA (1) CA2312885C (pt)
DE (1) DE69817611T2 (pt)
DK (1) DK1036794T3 (pt)
ES (1) ES2205574T3 (pt)
HK (1) HK1028769A1 (pt)
HU (1) HUP0004422A3 (pt)
ID (1) ID24929A (pt)
IL (1) IL135920A0 (pt)
NO (1) NO20002835L (pt)
NZ (1) NZ504457A (pt)
PL (1) PL191489B1 (pt)
PT (1) PT1036794E (pt)
RU (1) RU2223272C2 (pt)
SK (1) SK285703B6 (pt)
TR (1) TR200001600T2 (pt)
TW (1) TW502034B (pt)
WO (1) WO1999028320A1 (pt)
ZA (1) ZA9810490B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003146987A (ja) * 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
WO2001023361A1 (fr) * 1999-09-27 2001-04-05 Ono Pharmaceutical Co., Ltd. Derives de la pyrimidine, leur procede de preparation, et medicaments les contenant comme principe actif
IL154049A0 (en) 2000-07-31 2003-07-31 Dainippon Pharmaceutical Co Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
AU2004263515A1 (en) * 2003-08-05 2005-02-17 Vertex Pharmaceuticals Incorporated Condensed pyrimidine compounds as inhibitors of voltage-gated ion channels
WO2005080334A1 (ja) * 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 新規へテロ環化合物
EP1734820A4 (en) * 2004-04-16 2008-01-23 Neurogen Corp Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands
FR2870239B1 (fr) * 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
EP1874772A1 (en) * 2005-04-05 2008-01-09 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
MX2008011525A (es) * 2006-03-09 2008-09-18 Pharmacopeia Inc Inhibidores de mnk2 de 8-heteroarilpurina para el tratamiento de trastornos metabolicos.
US7915268B2 (en) * 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
AR063142A1 (es) * 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
ZA200902382B (en) 2006-10-19 2010-08-25 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
JP2009007273A (ja) 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8473571B2 (en) 2009-01-08 2013-06-25 Microsoft Corporation Synchronizing presentation states between multiple applications
CN102656172B (zh) * 2009-09-09 2016-03-23 大日本住友制药株式会社 8-氧代二氢嘌呤衍生物
JP2013508456A (ja) 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ， エルエルシー ヘテロアリール化合物の合成方法および精製方法
JP2014076947A (ja) * 2011-02-03 2014-05-01 Dainippon Sumitomo Pharma Co Ltd ２−オキシ置換８−オキソジヒドロプリン誘導体
EP2718464A1 (en) 2011-06-06 2014-04-16 Imperial Innovations Limited Methods to predict binding affinity of tspo imaging agents to tspo
EP3659599B1 (en) 2011-10-19 2022-12-21 Signal Pharmaceuticals, LLC 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for use in the treatment of glioblastoma multiforme
CA3125862A1 (en) 2011-12-02 2013-06-06 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9375443B2 (en) 2012-02-24 2016-06-28 Signal Pharmaceuticals, Llc Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib
CN102675315B (zh) * 2012-02-28 2015-04-01 中国人民解放军第四军医大学 含取代苯烷基的嘌呤类化合物和制备方法及应用
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
ES2638179T3 (es) 2013-01-16 2017-10-19 Signal Pharmaceuticals, Llc Compuestos de pirrolopirimidina sustituidos, composiciones de los mismos, y métodos de tratamiento con los mismos
KR102459285B1 (ko) 2013-04-17 2022-10-27 시그날 파마소티칼 엘엘씨 1-에틸-7-(2-메틸-6-(1H-1,2,4-트리아졸-3-일)피리딘-3-일)-3,4-디하이드로피라지노[2,3-b]피라진-2(1H)-온에 관한 약학 제제, 제조방법, 고체 형태 및 사용 방법
AU2014254058B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
CN105392499B (zh) 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
UA119538C2 (uk) 2013-04-17 2019-07-10 Сігнал Фармасьютікалз, Елелсі Лікування злоякісної пухлини дигідропіразинопіразинами
US9474757B2 (en) 2013-04-17 2016-10-25 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
KR102221029B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
JP2017514806A (ja) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
KR20170024120A (ko) 2014-07-14 2017-03-06 시그날 파마소티칼 엘엘씨 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
MX2021001186A (es) 2015-11-20 2022-10-11 Forma Therapeutics Inc Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
CN111699187A (zh) 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525595A1 (fr) 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
FR2582514B1 (fr) 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
DK273689A (da) 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
FR2632639B1 (fr) 1988-06-09 1990-10-05 Sanofi Sa Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent
US5840891A (en) 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
AU698419B2 (en) 1996-07-03 1998-10-29 Dainippon Sumitomo Pharma Co., Ltd. A novel purine derivative
JP2002501493A (ja) * 1997-04-22 2002-01-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｒｆアンタゴニストのチオフェノピリジン類
JP3814125B2 (ja) * 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬

Also Published As

Publication number Publication date
DK1036794T3 (da) 2003-12-22
CA2312885C (en) 2008-01-29
NO20002835D0 (no) 2000-06-02
CN1146566C (zh) 2004-04-21
RU2223272C2 (ru) 2004-02-10
HUP0004422A2 (hu) 2001-04-28
HK1028769A1 (en) 2001-03-02
AU744014B2 (en) 2002-02-14
TW502034B (en) 2002-09-11
PT1036794E (pt) 2003-11-28
NO20002835L (no) 2000-07-24
EP1036794A4 (en) 2001-12-12
TR200001600T2 (tr) 2000-11-21
ZA9810490B (en) 1999-05-20
JP3815966B2 (ja) 2006-08-30
US6372740B1 (en) 2002-04-16
DE69817611T2 (de) 2004-02-26
NZ504457A (en) 2001-12-21
HUP0004422A3 (en) 2001-10-29
PL191489B1 (pl) 2006-05-31
EP1036794A1 (en) 2000-09-20
ID24929A (id) 2000-08-31
EP1036794B1 (en) 2003-08-27
BR9815140A (pt) 2000-10-10
AR017796A1 (es) 2001-10-24
SK7972000A3 (en) 2001-03-12
ATE248169T1 (de) 2003-09-15
CA2312885A1 (en) 1999-06-10
PL340925A1 (en) 2001-03-12
DE69817611D1 (de) 2003-10-02
KR100494347B1 (ko) 2005-06-13
SK285703B6 (sk) 2007-06-07
AU1260499A (en) 1999-06-16
ES2205574T3 (es) 2004-05-01
CN1284076A (zh) 2001-02-14
WO1999028320A1 (fr) 1999-06-10
KR20010032686A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
IL135920A0 (en) 2-aryl -8-oxodihydropurine derivative, process for the preparation thereof, pharmaceutical composition containing the same and intermediate therefor
HUP0004024A3 (en) Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
HUP0001539A3 (en) 2-(1-iminoethylamino)ethyl-homocysteine, process for its preparation and pharmaceutical compositions containing the same
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
HUP9900974A3 (en) Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
HUP9603495A2 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-compounds, pharmaceutical compositions containing the same and process for their preparation
HUP9700358A3 (en) New oxazolidinon derivatives, process for their preparation and pharmaceutical compositions containing them
HUP9700328A3 (en) Heteroaryl-oxazolidinones, process for their preparation, pharmaceutical compositions containing the same, their use and intermediates
HUP0100431A3 (en) Adamantana derivatives, pharmaceutical compositions comprising them and process for preparing them
HUP9603494A3 (en) Hydroxycarboxamide derivatives, pharmaceutical compositions containing them, process for the preparation thereof
IL136938A0 (en) 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
HUP0001555A3 (en) Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
IL138280A0 (en) 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
HUP0102307A3 (en) Bispidine derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0000851A3 (en) Novel pyrimidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
HUP0000426A3 (en) Novel benzonaphthyridines, pharmaceutical compositions and use thereof and process for their preparation
HUP0102215A3 (en) Benzoylpyridazines, pharmaceutical compositions containing the same and process for their preparation
HUP9901739A3 (en) Aminoisoquinolines and aminothienopyridine derivatives, process for producing thereof and pharmaceutical compositions containing them
IL137494A0 (en) Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same
IL113103A0 (en) Piperidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HK1039122A1 (zh) 取代的6-苄基-4-氧代嘧啶，其製備方法以及含該化合物的藥物組合物
HUP9901485A2 (en) Heterocyclylcarboxamide derivatives, pharmaceutical compositions containing the same, process for their preparation and their use
HUP0001093A3 (en) Oxazolidines as 5-ht2a-antagonists, pharmaceutical compositions containing the same and process for their preparation
HUP9602868A3 (en) 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivative, pharmaceutical compositions containing the same and process for their preparation
GB9310075D0 (en) New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees